Zum Stand der Therapie der chronisch myeloischen Leukämie Erwachsener mit dem Mistelpräparat Helixor

Journal/Book: Ärzteztschrift für Naturheilverfahren. 1982; 23: 523-535.

Abstract: The therapeutic results of the cytostatic therapy are not satisfactory as regards palliation and also quo-ad vitam. A therapy with Helixor? (derived from Viscum album L.) is presented.The selective cytostatic effect on transformed cell lines, the cancerostatic effect and evidence of immuno-biological effect are discussed.To 30 cases with CML Helixor? was administered as combination therapy or mono-therapy. Their median survival was 55.7 months, the five years survival rate was about 50 per cent. Median survival of comparable populations of CML patients from the world literature is about 30 to 34 months. Taking into account the prognosis a comparison is made with a control including 199 cases. The median survival was 30 months, the five years survival rate was about 20 per cent. Provided that the prognosis are the same the ex. tension of the median survival for about 25.7 months and the increase In the rate o1 survival for 30 per cent is interpreted as possible therapeutic effect of Helixo?.

Keyword(s): Viscum album

Zurück | Weiter